FDA Issues 30 Warning Letters to Telehealth Companies for Compounded GLP-1 Marketing Violations

The FDA issued 30 warning letters on April 1, 2025, to telehealth companies marketing compounded versions of semaglutide and tirzepatide without meeting federal drug marketing requirements. The enforcement action focuses on violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 502(f)(1), which prohibits the marketing of unapproved drugs. These letters create immediate compliance exposure for pharmacies and wholesale drug distributors supplying these entities.

Regulatory Background

Compounded drugs are excluded from FDA approval requirements under two conditions established by the Drug Quality and Security Act (DQSA) of 2013. Section 503A permits traditional compounding pharmacies to prepare patient-specific prescriptions without submitting a New Drug Application (NDA), provided the drug is compounded based on an individual prescription and not marketed as a commercial product. Section 503B allows outsourcing facilities to compound drugs in larger batches for distribution to healthcare providers, but requires FDA registration, compliance with current good manufacturing practices (cGMP), and reporting obligations.

Neither pathway permits marketing compounded drugs as alternatives to FDA-approved products. Under 21 CFR 207.1, marketing a drug product requires submission of an NDA or Abbreviated New Drug Application (ANDA). The FD&C Act Section 502(f)(1) classifies any drug marketed without adequate directions for use as misbranded, unless exempted through an approved application.

GLP-1 receptor agonists semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are currently in shortage, listed on FDA's Drug Shortages Database. Under 21 USC 353a(b)(1)(A)(i)(III), pharmacies may compound versions of drugs on the shortage list only for individual patient prescriptions. The exemption does not authorize mass marketing or distribution of compounded versions as commercial alternatives.

Key Violations Cited in Warning Letters

The FDA's warning letters allege the following violations:

1. Marketing unapproved drugs: Telehealth platforms advertised compounded semaglutide and tirzepatide on websites, social media, and email campaigns without FDA-approved labeling or an NDA on file.

1. Failure to establish patient-specific prescriptions: Companies offered "get started" flows that facilitated prescription generation through brief online questionnaires, creating prescriptions for commercial distribution rather than individualized patient care.

1. Misbranding under Section 502(f)(1): Products lacked adequate directions for safe use by laypersons, as required for over-the-counter distribution. Prescription-only marketing without proper labeling constitutes misbranding.

1. Distribution beyond 503A and 503B authority: Several entities distributed compounded GLP-1s across state lines without registering as 503B outsourcing facilities or demonstrating compliance with cGMP requirements under 21 CFR Part 211.

The FDA set a 15-day response deadline for firms to outline corrective actions. Failure to respond may result in product seizure, injunctions, or referral to the Department of Justice for criminal prosecution under 21 USC 333.

Compliance Impact on Wholesale Drug Distributors and 3PLs

Wholesale drug distributors and third-party logistics providers (3PLs) handling shipments for these telehealth entities face direct compliance risks:

Trading partner qualification obligations: Under the Drug Supply Chain Security Act (DSCSA), wholesale distributors must verify that trading partners are authorized under 21 USC 360eee-1(a)(1). An entity marketing misbranded or unapproved drugs may not qualify as an authorized trading partner. Distributors sourcing from or shipping for flagged telehealth companies should immediately review transaction histories and assess whether products fall under the FDA's enforcement scope.

State licensure exposure: State boards of pharmacy enforce 503A and 503B compliance independently. A wholesale distributor licensed in a state where a flagged telehealth entity operates may face board inquiries regarding shipments of compounded GLP-1s. State pharmacy boards in California, Texas, Florida, and New York have active enforcement programs for compounded drug violations.

Cold chain protocol documentation: Compounded semaglutide and tirzepatide require refrigerated storage at 2–8°C. 3PLs handling these products must maintain temperature logs that demonstrate compliance with manufacturer specifications. If the FDA determines a product is adulterated due to improper storage, liability may extend to the logistics provider under 21 USC 331(k), which prohibits the shipment of adulterated drugs in interstate commerce.

NABP accreditation implications: Distributors holding NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation must comply with NABP Model Rules Section 8, which requires distributors to establish procedures for identifying and removing misbranded or adulterated drugs from the supply chain. An entity shipping products for a telehealth company under FDA warning may face VAWD suspension or revocation if due diligence procedures are found insufficient.

Distributors should conduct an immediate review of customer contracts, transaction data, and shipping records to identify exposure to the 30 entities named in the warning letters. The FDA has not publicly released the full list of recipients, but several companies have disclosed receipt through public statements and SEC filings.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registration — a baseline requirement for handling prescription drugs in interstate commerce. However, FDA registration alone does not indicate whether an entity maintains adequate procedures for identifying misbranded or unapproved drugs in its distribution network.

The average compliance score in the ColdChainCheck directory is 51/100, placing most entities in the "Fair" tier. This tier indicates basic state licensure and FDA registration, but limited verification of higher-order compliance signals such as NABP accreditation or clean enforcement history. Only 63 entities hold NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation, which requires distributors to establish due diligence procedures for removing adulterated or misbranded products from the supply chain.

73 entities in the directory have at least one FDA recall, warning letter, or enforcement action on record. While recalls do not automatically indicate current non-compliance, they signal prior quality or regulatory gaps. Distributors working with telehealth companies marketing compounded GLP-1s should cross-reference trading partner lists against ColdChainCheck's enforcement history data to identify entities with prior FDA scrutiny.

Recommended Actions for QA and Compliance Teams

• Review customer contracts for telehealth entities: Cross-reference current customer lists against publicly disclosed recipients of FDA warning letters. If a trading partner is named, suspend shipments pending review of the entity's corrective action plan submitted to the FDA.

• Verify 503B registration for compounding suppliers: Use ColdChainCheck's directory search to confirm whether pharmacies supplying compounded semaglutide or tirzepatide are registered as 503B outsourcing facilities. Facilities compounding for interstate distribution without 503B registration operate outside federal authority.

• Audit transaction histories for GLP-1 shipments: Pull all transaction data for semaglutide and tirzepatide shipments over the past 12 months. Flag transactions where the receiving entity is not a licensed pharmacy, physician office, or hospital — a potential indicator of direct-to-consumer marketing that falls outside 503A/503B exemptions.

• Document due diligence procedures: If your state board of pharmacy or FDA district office issues an inquiry, compliance teams must demonstrate that trading partner qualification processes screened for marketing violations. NABP-accredited distributors should ensure VAWD compliance files include evidence of customer screening against FDA enforcement databases.

ColdChainCheck continuously monitors FDA enforcement actions, state board disciplinary proceedings, and NABP accreditation status changes. For ongoing coverage of compounded drug regulations and DSCSA compliance, refer to the compliance guides section.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Readers should consult with qualified legal counsel and verify all regulatory requirements with the FDA, state boards of pharmacy, and other applicable authorities before making compliance decisions.